Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ENROLLING BY INVITATION
NCT05623332

DETECT (Detecting Endometriosis inTEgrins Using teChneTium-99m Imaging Study)

Sponsor: University of Oxford

View on ClinicalTrials.gov

Summary

Endometriosis is a common gynaecological disease affecting 10% of the female population due to the presence of uterus-like tissue outside of the uterus, often in the pelvis. The disease causes severe lower abdominal pain mostly during the monthly period, during or after sexual intercourse, and when emptying the bowel and bladder. Currently, imaging methods such as ultrasound are ineffective at diagnosing the most common type of endometriosis, pelvic endometriosis. Therefore, we are heavily reliant on invasive surgery to make the diagnosis. This study aims to investigate the presence of binding proteins (integrins) in endometriotic tissue which will expand our understanding of endometriosis and could be used as a target to develop a non-invasive imaging test in the future. Women with symptoms consistent with endometriosis, who are due to undergo surgery to diagnose endometriosis at the EndoCare Unit in Oxford, will be eligible to participate. To attempt to visualise the integrins, participants will be asked to attend 2-7 days before their surgery to undergo an imaging scan with a molecular marker that has been found to highlight integrins in other conditions. The possibility of machine learning enhancement of integrin expression will be tested. The findings on the scan will be compared to the findings at surgery. Samples during surgery of endometriosis tissues, the endometrium, and salty water that has been flushed through the uterus, will be analysed in the lab to look for differences in the amount of integrin present in women with and without endometriosis and whether factors such as the phase of the menstrual cycle or hormonal treatment effect the amount seen.

Official title: Detecting Endometriosis inTEgrins Using teChneTium-99m Imaging Study

Key Details

Gender

FEMALE

Age Range

18 Years - 80 Years

Study Type

OBSERVATIONAL

Enrollment

25

Start Date

2023-03-01

Completion Date

2024-10

Last Updated

2024-06-14

Healthy Volunteers

Not specified

Conditions

Interventions

DIAGNOSTIC_TEST

Maraciclatide

Imaging marker that binds to AVB3/5 lesions

Locations (1)

John Radcliffe Hospital

Oxford, OXON, United Kingdom